<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03444883</url>
  </required_header>
  <id_info>
    <org_study_id>IL49NE03</org_study_id>
    <nct_id>NCT03444883</nct_id>
  </id_info>
  <brief_title>Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERD</brief_title>
  <official_title>A Multicenter, Randomized, Parallel, Double Blind, Placebo-controlled Phase III Study to Evaluate Safety and Efficacy of Ilaprazole 20mg in Patients With Non-erosive Reflux Disease(NERD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Il-Yang Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Il-Yang Pharm. Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Ilaprazole 20 mg in
      patients with non-erosive reflux disease. This study intends to demonstrate the clinical
      superiority of Ilaprazole 20 mg to placebo administered once daily for 4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A mulicenter, randomized, parallel, double blind, placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of loss of esophagitis symptom at 4 weeks of treatment vs pre-dose</measure>
    <time_frame>4 weeks(28 days)</time_frame>
    <description>Percentage of subjects who were assessed as having 'lost' the frequency and intensity of typical esophagitis symptoms by RDQ assessment at 4 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chang in esophagitis symptom score at 4 weeks of treatment vs pre-dose</measure>
    <time_frame>4 weeks(28 days)</time_frame>
    <description>The mean scores for esophagitis symptom (heartburn and/or acid regurgitation) frequency and intensity assessed with RDQ (Questions a, b/c, d) and the change in mean score across both domains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PAGI-QoL score at 4 weeks of treatment vs pre-dose</measure>
    <time_frame>4 weeks(28 days)</time_frame>
    <description>The change in mean score for quality of life assessed with PAGI-QoL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Non-erosive Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10mg Ilaprazole x 2 tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10mg placebo of Ilaprazole x 2 tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ilaprazole</intervention_name>
    <description>10mgx2 tablet once daily for weeks</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged ≥ 19 years and ≤ 80 years

          2. Diagnosed with non-erosive reflux disease meeting all of the following criteria:

             2-1) At least either heartburn or acid regurgitation has persisted for at least past 3
             months before screening 2-2) Have experienced at least either heartburn or acid
             regurgitation of moderate or higher intensity on at least 2 days of 7 days prior to
             initiation of the investigational product 2-3) Esophageal mucosal breaks by LA
             Classification are not observed on upper gastrointestinal endoscopy at screening

          3. Voluntarily provide written informed consent to participate in this study

        Exclusion Criteria:

          1. Esophageal stenosis, ulcerative stenosis, esophagogastric varices, Barrett esophagus,
             active peptic ulcer, gastrointestinal bleeding, or malignancy confirmed by past upper
             gastrointestinal endoscopy

          2. Abnormal value on laboratory test at screening:

          3. Clinically significant abnormal findings on ECG (major arrhythmia, multifocal PVC,
             second-degree or higher AV block, etc.) within 3 months prior to screening

          4. Have taken H2 receptor antagonists (H2RA), prostaglandin preparations, mucosal
             protective drugs, prokinetics, etc. at usual dosage within 2 weeks prior to initiation
             of the investigational product, or has taken PPIs at usual dosage within 4 weeks prior
             to initiation of the investigational product

          5. Expected to continuously take nonsteroidal antiinflammatory drugs (NSAIDs) including
             aspirin (≥ 325 mg/day) or steroid preparations during the study

          6. Surgical or medical condition that may significantly influence the absorption,
             distribution, metabolism or excretion of drug, including but not limited to: history
             of major gastrointestinal surgery such as gastrectomy, gastroenterostomy, colectomy,
             gastric bypass, gastric ligation or gastric banding

          7. Zollinger-Ellison syndrome; past history of alcoholism or drug abuse

          8. Past history of allergic symptoms (rash, fever, pruritus, etc.) or hypersensitivity to
             any ingredient of the study drug

          9. Past history of treated or untreated malignancy, with or without local recurrence or
             metastasis, within 5 years prior to screening (with exception of local basal cell
             carcinoma of skin)

         10. Pregnant or nursing women

         11. Women of childbearing potential who do not use proper contraception during the study

         12. Active liver disease; ALT or AST &gt; ULN x 2 at screening; or history of hepatic
             encephalopathy, esophageal varix, or portacaval shunt

         13. Receiving renal dialysis or history of kidney transplantation or presence of severe
             renal impairment (stage 4 or 5 chronic renal disease)

         14. Participated in another clinical study and took an investigational product within 3
             months prior to screening

         15. Considered by the investigator to be ineligible to participate in this study for other
             reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>DongHo Lee, MD.PhD</last_name>
    <phone>+82-31-787-7000</phone>
    <email>dhljohn@yahoo.co.kr</email>
  </overall_contact>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2018</study_first_submitted>
  <study_first_submitted_qc>February 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

